Capecitabine Tablets 500 Mg – Generic Xeloda

Capecitabine Tablets 500 Mg – Generic Xeloda is an oral chemotherapy medication used in the treatment of various cancers, including breast cancer and colorectal cancer. It is a prodrug that is converted into 5-fluorouracil (5-FU) inside the body, allowing targeted action within tumor tissues. This selective activation helps reduce damage to healthy cells while effectively inhibiting cancer growth. In oncology treatment strategies, targeted therapies such as Dasatinib Tablets 100 Mg – Generic Sprycel may be used in specific leukemia cases, while alternative dosing options like Dasatinib Tablets 50 Mg – Generic Sprycel are prescribed based on patient condition and treatment response.

Mechanism of Action

Prodrug Conversion

Capecitabine Tablets 500 Mg is converted into its active form, 5-fluorouracil (5-FU), within cancer cells, allowing localized anticancer activity.

DNA and RNA Inhibition

The active metabolite interferes with DNA and RNA synthesis in cancer cells, leading to inhibition of tumor growth and cell death. For detailed research insights, refer to National Cancer Institute (NCI) and for safety information, consult Mayo Clinic – Capecitabine Drug Information.

Medical Uses

Capecitabine Tablets 500 Mg – Generic Xeloda is used in:

• Breast cancer
• Colorectal cancer
• Gastric cancer (in some cases)

It may be used alone or in combination with other chemotherapy agents depending on the treatment plan.

Dosage and Administration

Capecitabine Tablets 500 Mg is usually taken twice daily within 30 minutes after meals, in cycles as prescribed by an oncologist. The dosage depends on body surface area, type of cancer, and patient tolerance. In broader cancer treatment approaches, Dasatinib Tablets 100 Mg – Generic Sprycel is used in hematologic malignancies, while dose variations such as Dasatinib Tablets 50 Mg – Generic Sprycel may be considered based on individual patient requirements.

Clinical Effectiveness

Clinical studies have demonstrated that Capecitabine is effective in improving survival rates and reducing tumor progression in patients with breast and colorectal cancers. Its oral administration offers convenience compared to intravenous chemotherapy.

Safety and Side Effects

Common Side Effects

• Diarrhea
• Nausea and vomiting
• Hand-foot syndrome (redness, swelling of palms and soles)
• Fatigue

Serious Risks

• Severe diarrhea and dehydration
• Cardiotoxicity (rare)
• Bone marrow suppression

Regular monitoring is essential during treatment. For more details, refer to Mayo Clinic – Capecitabine Drug Information.

Contraindications and Precautions

Capecitabine Tablets 500 Mg should be used with caution in:

• Patients with kidney impairment
• Individuals with cardiovascular conditions
• Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency

It should not be used during pregnancy. Medical supervision is required.

Drug Interactions

Capecitabine Tablets 500 Mg may interact with anticoagulants, other chemotherapy drugs, and medications affecting liver enzymes. Patients should inform their healthcare provider about all medications they are taking. For research-based insights, refer to National Cancer Institute (NCI).

FAQs